Company profile
Immunotech Laboratories, Inc.
OTC: IMMB · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 39
v0.1 · 5/100 weight · pillars only
↑ listing tenure, return on assets · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$493.0k
Employees
4
as of 2026-08-28
Market cap
$115.0k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02016
Net income-$493.0k-$493.0k2016
Operating income-$470.4k-$470.4k2016
Total assets$10.5M$10.5M2016
Liabilities$5.7M$5.7M2016
Equity$4.8M$4.8M2016
Revenue trend
FY2001 – FY2016 · USD
FY01
FY02
FY03
FY04
FY05
FY09
FY13
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Immunotech Laboratories, Inc.’s revenue?
Immunotech Laboratories, Inc. booked $0 in FY2016 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
DrazCanna, Inc.——GB Sciences, Inc.——Manzo Pharmaceuticals, Inc.57CLink Reservations Inc.——NanoSphere Health Sciences Inc.——Many Bright Ideas Technologies Inc.——Neighbors
Los Angeles →Key facts
CEOJennifer L. Bath
SectorHealthcare
IndustryBiotechnology
HeadquartersMonrovia, CA
ExchangeOTC: IMMB
Employees4
IPO date2001-12-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.